A simple tool for administering Cytogam^®

Use this calculator as a quick, easy guide to finding the correct dose of Cytogam^® based on the patient's body weight, type of transplant and week of infusion post-transplant. The maximum recommended total dosage per infusion is 150 mg/kg. Please refer to the full Prescribing Information for guidance on administration schedule, infusion rates and subsequent doses. Close monitoring of the patient is necessary throughout the infusion process.

These calculations are to be used for Cytogam^® only and are applicable in the prophylaxis of CMV associated with transplantation of kidney, lung, liver, pancreas and heart.

Dosing Schedule

Instructions

To determine the correct dose of Cytogam^® please enter:

Dosage:

Patient's Body Weight:

Please Note: This calculator performs calculations in kg and will convert any weight in lbs to the nearest kg before calculating the dosage. The weight conversion used is 1 kg = 2.2 lbs. Additionally, the number of vials calculated represents the minimum number of vials to obtain the calculated dose. The number of vials is not the actual dose. (1 Vial = 2500 mg)

Dose:

© 2008 CSL Behring

Important Safety Information

Cytogam^® is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart.

Cytogam^® is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations and in persons with selective immunoglobulin A deficiency who have known antibodies to IgA.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients predisposed to acute renal failure include patients with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentrations available and the minimum rate of infusion practicable.

Increases in serum creatinine and blood urea nitrogen (BUN) have been observed as soon as one to two days following IGIV infusion. Progression to oliguria or anuria requiring dialysis has been observed.

Cytogam^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Minor reactions, such as flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing, were the most frequent adverse reactions observed during the clinical trials for Cytogam^®.

For more information about Cytogam^®, please see the full prescribing information.

Cytogam^® is a registered trademark of CSL Behring AG.

A simple tool for administering Cytogam®

Dosing Schedule

Instructions

© 2008 CSL Behring

Important Safety Information

A simple tool for administering Cytogam^®